606|10000|Public
5000|$|Basic Guidelines of Judicious Therapeutic <b>Use</b> <b>of</b> <b>Antimicrobials</b> ...|$|E
5000|$|Regulate {{and promote}} {{rational}} use of medicines, including in animal husbandry, and ensure proper patient care; reduce <b>use</b> <b>of</b> <b>antimicrobials</b> in food-producing animals.|$|E
5000|$|Hillerton JE, Irvine CR, Bryan MA, Scott D, Merchant SC. (2016) <b>Use</b> <b>of</b> <b>antimicrobials</b> {{for animals}} in New Zealand, and in {{comparison}} with other countries. New Zealand Veterinary Journal, Forthcoming articles, pp 1-7, Mar 2016; DOI: 10.1080/00480169.2016.1171736 ...|$|E
40|$|This second OIE {{annual report}} on the <b>use</b> <b>of</b> <b>antimicrobial</b> agents {{intended}} for use in animals gives the first ever glimpse into the global <b>use</b> <b>of</b> <b>antimicrobial</b> agents adjusted for animal biomass for 2014, and presents the overall findings of the second annual data collection on the <b>use</b> <b>of</b> <b>antimicrobial</b> agents in animals, providing a global and regional analysis from 2013 to 2016...|$|R
30|$|Prevention of pin-track {{infection}} is, therefore, wise. Several studies describe varying {{methods for}} the control or prevention of infection. These methods include: technique of insertion such as prevention of thermal injury [8]; <b>use</b> <b>of</b> <b>antimicrobial</b> coated pins [9, 10, 11]; silver-coated pins [12]; and the <b>use</b> <b>of</b> <b>antimicrobial</b> impregnated patches [13].|$|R
40|$|The Health Council of the Netherlands {{has issued}} {{a report on the}} risk of {{development}} of resistance among bacteria as result <b>of</b> the <b>use</b> <b>of</b> antibiotics as growth promotors in livestock farming. The committee appointed by the Health Council conclude that the <b>use</b> <b>of</b> <b>antimicrobial</b> growth promotors contributes to the problem of resistance among human pathogens. The conclusions are based on evidence regarding the development of resistance in livestock as the result <b>of</b> the <b>use</b> <b>of</b> <b>antimicrobial</b> growth promotors, the possibility of colonisation/infection of humans with resistance bacteria from the intestinal flora of productive livestock, and the transfer of resistance genes from livestock bacteria to human pathogenic microorganisms. Effective measures for the limitation of the public health risk should focus on termination <b>of</b> the <b>use</b> <b>of</b> <b>antimicrobial</b> growth promotors that confer resistance to (relate) antibiotics currently used (or which will be available) to treat patients suffering from bacterial infections. In addition, the committee advised ending the <b>use</b> <b>of</b> <b>antimicrobial</b> growth promotors in 3 years...|$|R
50|$|By 2001 this {{practice}} {{had grown so}} much that {{a report by the}} Union of Concerned Scientists found that nearly 90% of the total <b>use</b> <b>of</b> <b>antimicrobials</b> in the United States was for non-therapeutic purposes in agricultural production.|$|E
50|$|With {{increasing}} global {{concern over}} development of antimicrobial resistance, the CVMA {{has taken an}} active role in Canada on the responsible <b>use</b> <b>of</b> <b>antimicrobials.</b> The CVMA has urged the government for further regulatory changes to provide increased veterinary oversight of antibiotic use in Canada. In 2015, the CVMA revised their statement to include a position on <b>use</b> <b>of</b> <b>antimicrobials</b> of high importance in human medicine (VDD Category I to III), stating they should only be used under veterinary oversight with a veterinary prescription. The CVMA, in conjunction with Health Canada and other partner organizations, developed a Therapeutic Decision Cascade for Animal and Public Safety. This document is intended to assist veterinarians in prescribing drugs, including antimicrobials, in a conscientious way for both animals and public health.|$|E
50|$|Approximately 90% of {{the total}} <b>use</b> <b>of</b> <b>antimicrobials</b> in the United States was for non-therapeutic {{purposes}} in agricultural production. Livestock production {{has been associated with}} increased antibiotic resistance in bacteria, and has been associated with the emergence of microbes which are resistant to multiple antimicrobials (often referred to as superbugs).|$|E
40|$|To the Editor: The {{inappropriate}} and excessive <b>use</b> <b>of</b> <b>antimicrobial</b> agents has cultivated {{the development and}} progression <b>of</b> <b>antimicrobial</b> resistance worldwide, which has been recognised {{as a threat to}} global health and safety. [1] In response to this alarming growth in antimicrobial resistance, antimicrobial stewardship initiatives, which aim to improve the judicious <b>use</b> <b>of</b> <b>antimicrobial</b> agents, have gained global support. [2] The Antimicrobial Resistance Strategy Framework in South Africa (SA) recognises the education of healthcare professionals as a strategy for containment <b>of</b> <b>antimicrobial</b> resistance in SA. [3...|$|R
50|$|Two {{cases of}} {{infection}} in children {{were reported in}} 1993. They recovered without the <b>use</b> <b>of</b> <b>antimicrobial</b> therapy.|$|R
40|$|The IDF Guide to Prudent <b>Use</b> <b>of</b> <b>Antimicrobial</b> Agents in Dairy Production aims at {{providing}} a framework {{to support the}} responsible <b>use</b> <b>of</b> <b>antimicrobial</b> agents on dairy farms. The guidelines stress the importance and need for a whole supply chain approach to ensure food safety. The focus of this publication is on desired outcomes rather than on specific, prescriptive actions or processes. It provides examples of recommended practices for all participants in the regulation, supply and <b>use</b> <b>of</b> <b>antimicrobial</b> agents at farm level. Consultation across these sectors was undertaken throughout the development process, to ensure the guide is robust. The Guide includes an overview of relevant Good Agricultural Practice (GAP) as well as fact sheets to enable the key participants in the dairy supply chain to effectively collaborate in producing high quality milk...|$|R
50|$|The {{strain of}} Lactobacillus crispastus was {{originally}} isolated from a pouch in chickens gullet {{and is considered}} {{to be one of the}} strongest H2O2-producing lactobacilli. Like many other Lactobacillus species, it can be severely altered by changes to the immune system, hormone levels and from the <b>use</b> <b>of</b> <b>antimicrobials.</b> Lactobacillus crispatus is a normal inhabitant of the lower reproductive tract in healthy women.|$|E
50|$|More recently, {{there has}} been {{increased}} concern {{about the use of}} anti-microbials in animals (including pets, livestock, and companion animals) contributing to the rise in antibiotic resistant infections in humans. The <b>use</b> <b>of</b> <b>antimicrobials</b> has been linked to the rise of resistance in every drug and species where it has been studied, including humans and livestock. However, the role of antibiotic use in food animals - in contrast to the use of antibiotics in humans - in the rise of resistant infections in humans is in dispute. The <b>use</b> <b>of</b> <b>antimicrobials</b> in various forms is widespread throughout animal industry, and is presented as key to preventing animal suffering and economic loss. It is linked by some activist groups to animal welfare concern, large scale commercial agriculture, international food trade, agricultural protectionist laws, environmental protection (including climate change) and other topics, which make the aims of some groups {{on both sides of the}} debate difficult to untangle.|$|E
50|$|In {{a recent}} years, {{antimicrobial}} stewardship teams in hospitals have encouraged optimal <b>use</b> <b>of</b> <b>antimicrobials.</b> The goals of antimicrobial stewardship are to help practitioners {{pick the right}} drug at the right dose and duration of therapy while preventing misuse and minimizing the development of resistance. Stewardship may reduce the length of stay {{by an average of}} slightly over 1 day while not increasing the risk of death.|$|E
40|$|In a {{population-based}} {{case-control study}} of community acquired Clostridium difficile-associated disease (CDAD), we matched 1, 233 cases to 12, 330 controls. CDAD risk increased 3 -fold with <b>use</b> <b>of</b> any <b>antimicrobial</b> agent and 6 -fold with <b>use</b> <b>of</b> fluoroquinolones. Prior <b>use</b> <b>of</b> <b>antimicrobial</b> agents {{did not affect}} risk for CDAD after 6 months...|$|R
40|$|Metals such as mercury, arsenic, {{copper and}} silver {{have been used}} in various forms as <b>antimicrobials</b> for {{thousands}} <b>of</b> years with until recently, little understanding of their mode of action. The discovery of antibiotics and new organic antimicrobial compounds during the twentieth century saw a general decline in the clinical <b>use</b> <b>of</b> <b>antimicrobial</b> metal compounds, {{with the exception of the}} rediscovery <b>of</b> the <b>use</b> <b>of</b> silver for burns treatments and niche uses for other metal compounds. Antibiotics and new antimicrobials were regarded as being safer for the patient and more effective than the metal-based compounds they supplanted. Bacterial metal ion resistances were first discovered in the second half of the twentieth century. The detailed mechanisms of resistance have now been characterized in a wide range of bacteria. As the <b>use</b> <b>of</b> <b>antimicrobial</b> metals is limited, it is legitimate to ask: are antimicrobial metal resistances in pathogenic and commensal bacteria important now? This review details the new, rediscovered and 'never went away' <b>uses</b> <b>of</b> <b>antimicrobial</b> metals; examines the prevalence and linkage <b>of</b> <b>antimicrobial</b> metal resistance genes to other antimicrobial resistance genes; and examines the evidence for horizontal transfer of these genes between bacteria. Finally, we discuss the possible implications of the widespread dissemination of these resistances on re-emergent <b>uses</b> <b>of</b> <b>antimicrobial</b> metals and how this could impact upon the antibiotic resistance problem...|$|R
50|$|In April 2016 it was {{the first}} European health agency to {{recommend}} the <b>use</b> <b>of</b> <b>Antimicrobial</b> copper-alloy touch surfaces as an infection prevention and control measure.|$|R
50|$|Rising drug {{resistance}} is caused mainly by improper <b>use</b> <b>of</b> <b>antimicrobials</b> in humans {{as well as}} in animals, and spread of resistant strains between the two. Antibiotics increase selective pressure in bacterial populations, causing vulnerable bacteria to die; this increases the percentage of resistant bacteria which continue growing. With resistance to antibiotics becoming more common there is greater need for alternative treatments. Calls for new antibiotic therapies have been issued, but new drug development is becoming rarer.|$|E
50|$|There {{has been}} massive use of {{antibiotics}} in animal husbandry. The most abundant <b>use</b> <b>of</b> <b>antimicrobials</b> worldwide are in livestock; they are typically distributed in animal feed or water for purposes such as disease prevention and growth promotion.Debates have arisen surrounding {{the extent of the}} impact of these antibiotics, particularly antimicrobial growth promoters, on human antibiotic resistance. Although some sources assert that there remains a lack of knowledge on which antibiotic use generates the most risk to humans, policies and regulations have been placed to limit any harmful effects.|$|E
5000|$|The FDA now enforces {{regulations}} in the US requiring testing of certain imported products for antimicrobial agents under Import Alert 16-131. [...] The Import Alert provides that the <b>use</b> <b>of</b> <b>antimicrobials</b> during the {{various stages of}} aquaculture, including malachite green, nitrofurans, fluoroquinolones, and gentian violet, may contribute to an increase of antimicrobial resistance in human pathogens and that prolonged exposure to nitrofurans, malachite green, and gentian violet {{has been shown to}} have a carcinogenic affect. [...] In a consumer brochure, the FDA describes the reasoning for enforcement under the import alert: ...|$|E
25|$|The U.S. E.P.A. oversees a {{stewardship}} plan {{to promote}} the responsible <b>use</b> <b>of</b> <b>Antimicrobial</b> Copper. Further information about the making accurate claims about Antimicrobial Copper is also available.|$|R
50|$|An {{antimicrobial}} is {{an agent}} that kills microorganisms or stops their growth. Antimicrobial medicines can be grouped {{according to the}} microorganisms they act primarily against. For example, antibiotics are used against bacteria and antifungals are used against fungi. They can also be classified according to their function. Agents that kill microbes are called microbicidal, while those that merely inhibit their growth are called biostatic. The <b>use</b> <b>of</b> <b>antimicrobial</b> medicines to treat infection is known as antimicrobial chemotherapy, while the <b>use</b> <b>of</b> <b>antimicrobial</b> medicines to prevent infection is known as antimicrobial prophylaxis.|$|R
40|$|Antimicrobial {{resistance}} in the ICU is characterized by increasing overall resistance rates among gram-negative and gram-positive pathogens and increased frequency el multidrug-resistant organisms. In addition to basic principles el appropriate drug selection for empiric and definitive therapy, other specific strategies that may decrease problems el resistance through improved use el antimicrobials include appropriate application of pharmacokinetic and pharmacodynamic principles to <b>antimicrobial</b> <b>use,</b> aggressive dosing <b>of</b> <b>antimicrobials,</b> <b>use</b> <b>of</b> broad-spectrum and combination antimicrobial therapy for initial treatment, decreased duration el antimicrobial therapy, hospital formulary-based <b>antimicrobial</b> restrictions, <b>use</b> <b>of</b> <b>antimicrobial</b> protocols and guidelines, programs for restriction <b>of</b> target <b>antimicrobials,</b> scheduled <b>antimicrobial</b> rotation, and <b>use</b> <b>of</b> <b>antimicrobial</b> management programs. Combinations of various approaches may offer the best potential for effectively intervening in and reducing the spread of resistant pathogens in critically ill patients...|$|R
5000|$|Slots is {{currently}} {{a professor in the}} department of periodontology at the Herman Ostrow School of Dentistry of USC. [...] He is editor-in-chief of Periodontology 2000 and editor-in-chief emeritus of the Journal of Periodontal Research, as well as the author of numerous articles related primarily to the <b>use</b> <b>of</b> <b>antimicrobials</b> and antibiotics in the treatment of periodontal disease. [...] He is particularly known for advocating the use of diluted bleach as both a mouth rinse and a subgingival irrigant in a clinical setting as an adjunctive treatment for periodontal diseases.|$|E
50|$|The anaerobes often {{recovered}} include Prevotella bivia, Prevotella disiens, and Peptostreptococcus, Porphyromonas and Clostridium spp. Bacteroides fragilis {{group is}} rarely recovered in these infections compared to intra-abdominal infection. Actinomyces spp. and Eubacterium nodatum are often recovered in infections associated with intrauterine devices. Mobiluncus spp. can {{be associated with}} bacterial vaginosis. The aerobic bacteria also found mixed with these anaerobic bacteria include Enterobacteriaceae, Streptococcus spp. (including groups A and B), Neisseria gonorrhoeae, Chlamydia spp. and Mycoplasma hominis. Free gas in the tissues, abscess formation and foul-smelling discharge is commonly associated with the presence of anaerobic bacteria. Treatment of these infections includes the <b>use</b> <b>of</b> <b>antimicrobials</b> active against all of the potential aerobic and anaerobic bacterial pathogens. Antimicrobials against sexually transmissible pathogens should also be administered.|$|E
50|$|Diagnosis of the {{bacterium}} in humans was traditionally based on clinical findings, {{and culture and}} seriological testing, but false negatives have been a problem due to easy death of P. multocida, and serology cannot differentiate between current infection and previous exposure. The quickest and most accurate method for confirming an active P. multocida infection is molecular detection using polymerase chain reaction.This bacterium can be effectively treated with Î²-lactam antibiotics, which inhibit cell wall synthesis. It can also be treated with fluoroquinolones or tetracyclines; fluoroquinolones inhibit bacterial DNA synthesis and tetracyclines interfere with protein synthesis by binding to the bacterial 30S ribosomal subunit. Despite poor in vitro susceptibility results, macrolides (binding to the ribosome) also can be applied, certainly {{in the case of}} pulmonary complications. Due to the polymicrobial etiology of P. multocida infections, treatment requires the <b>use</b> <b>of</b> <b>antimicrobials</b> targeted at the elimination of both aerobic and anaerobic, Gram-negative bacteria. As a result, amoxicillin-clavulanate (a beta-lactamase inhibitor/penicillin combination) is seen as the treatment of choice.|$|E
3000|$|Introduction: Hospital Antimicrobial Stewardship (AMS) {{programs}} have achieved savings and more rational <b>use</b> <b>of</b> <b>antimicrobial</b> treatments. However, intervention over <b>antimicrobial</b> treatment <b>of</b> critical patients with hematologic disease is highly complicated [...]...|$|R
5000|$|The 2007 {{definition}} by the Society for Healthcare Epidemiology of America (SHEA) defines AMS as a [...] "set of coordinated {{strategies to}} improve the <b>use</b> <b>of</b> <b>antimicrobial</b> medications with the goal to ...|$|R
50|$|Antimicrobial labels. With {{the growth}} in {{hospital}} acquired infections such as MRSA and E-Coli the <b>use</b> <b>of</b> <b>antimicrobial</b> labels in infection sensitive areas of hospitals are helping in combating these types of microbes.|$|R
50|$|Antimicrobial {{stewardship}} (AMS) is {{the systematic}} effort {{to educate and}} persuade prescribers of antimicrobials to follow evidence-based prescribing, in order to stem antibiotic overuse, and thus antimicrobial resistance. AMS has been an organized effort of specialists in infectious diseases,both in Internal Medicine and Pediatrics with their respective peer-organizations, hospital pharmacists, the public health community and their professional organizations since the late 1990s. It has first been implemented in hospitals. In the U.S., {{within the context of}} physicians' prescribing freedom (choice of prescription drugs), AMS has largely been voluntary self-regulation in the form of policies and appeals to adhere to a prescribing self-discipline. At hospitals, this may take the form of an antimicrobial stewardship program. As of 2014, only the state of California has made this type of AMS mandatory by law. Within the context of commercial and over-the-counter <b>use</b> <b>of</b> <b>antimicrobials,</b> legally mandated AMS has begun with FDA rules that triclosan be phased out of consumer-grade soaps due to lack of good evidence that such use improves public health.|$|E
40|$|Abstract Treatment of {{mastitis}} {{should be}} based on bacteriological diagnosis and take national and international guidelines on prudent <b>use</b> <b>of</b> <b>antimicrobials</b> into account. In acute mastitis, where bacteriological diagnosis is not available, treatment should be initiated based on herd data and personal experience. Rapid bacteriological diagnosis would facilitate the proper selection of the antimicrobial. Treating subclinical mastitis with antimicrobials during lactation is seldom economical, because of high treatment costs and generally poor efficacy. All mastitis treatment should be evidence-based, i. e., the efficacy of each product and treatment length should be demonstrated by scientific studies. Use of on-farm written protocols for mastitis treatment promotes a judicious <b>use</b> <b>of</b> <b>antimicrobials</b> and reduces the <b>use</b> <b>of</b> <b>antimicrobials.</b> </p...|$|E
40|$|Strategies {{to improve}} the <b>use</b> <b>of</b> <b>antimicrobials</b> and to limit the {{acquisition}} and spread of resistance are of paramount importance and may influence directly the epidemiology of nosocomial infections. The increasing incidence of nosocomial infections is strongly related to both suboptimal <b>use</b> <b>of</b> <b>antimicrobials</b> and poor compliance with optimal patient care practices. Cross-transmission of resistant bacteria in hospitals results from poor adherence to infection control measures such as hand hygiene and standard precautions, and leads to an increasing reservoir of resistant organisms, that further facilitate the development of resistance. The strategies proposed in this review target both the appropriate <b>use</b> <b>of</b> <b>antimicrobials</b> in order to decrease resistance acquisition, and improvements in health care practices to reduce cross-transmission...|$|E
40|$|The <b>use</b> <b>of</b> <b>antimicrobial</b> {{agents in}} food animals has caused concern {{regarding}} the impact these uses have on human health. <b>Use</b> <b>of</b> <b>antimicrobial</b> agents in {{animals and humans}} results in the emergence and dissemina-tion of resistant bacteria. Resistant bacteria from food animals may be passed through the food chain to hu-mans resulting in resistant infections. Increasing resistance to antimicrobial agents {{that are important in}} the treatment of human diseases, such as fluoroquinolones and third-generation cephalosporins for the treatment of Salmonella and Campylobacter infections, has significant public health implications. Efforts to mitigate the effects of increasing resistance require collaboration by several partners, including the farming, veterinary, medical, and public health communities. 37...|$|R
40|$|Organic {{farming is}} {{among other things}} characterised by a more {{restrictive}} <b>use</b> <b>of</b> <b>antimicrobial</b> agents. A low occurrence <b>of</b> <b>antimicrobial</b> resistance {{can be regarded as}} a sign of quality. However, to be acceptable a limited <b>use</b> <b>of</b> <b>antimicrobial</b> agents has to be without adverse negative effect on animal welfare to be acceptable. In this study methods to perform a continuous surveillance for antimicrobial resistance at herd level will be used to compare the occurrence of resistance between organic and conventional dairy herds. In addition the treatment pattern of animals in organic herds will be studied Based upon this information guidelines for disease treatment will be developed and implemented as herd specific treatment strategies which meet the demand for animal welfare and minimises the risk for antimicrobial resistance...|$|R
40|$|This paper {{presents}} {{the rationale for}} the <b>use</b> <b>of</b> <b>antimicrobial</b> therapy in the dog according to the body system or organ in which an infection is located. In so doing, it correlates information on the abilities possessed by the different groups <b>of</b> <b>antimicrobial</b> drugs to penetrate sites of infection in particular body tissues. It also presents information on the clinical results reported after the <b>use</b> <b>of</b> particular <b>antimicrobial</b> drugs in the treatment of infections involving specific body systems and organs. The information provided on dose rates is qualitative rather than quantitative. Copyrigh...|$|R
